May 23, 2022 by Chain Drug Review
Albert Bourla, BioNTech SE, Pfizer, Pfizer-BioNTech COVID-19 Vaccine in children 6 months to under 5 years of age
Leading Headlines, Pharmacy
NEW YORK — Pfizer Inc. and BioNTech SE announced Monday topline safety, immunogenicity and vaccine efficacy data from a Phase 2/3 trial evaluating a third 3-µg dose of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months to under 5 years of age. Following a third dose in this age group, the vaccine was found to
February 14, 2022 by Chain Drug Review
Opern Targets, Pfizer
Leading Headlines, Pharmacy
HINXTON, UK — Open Targets, a consortium focused on drug target identification, prioritisation, and validation, announced today that Pfizer has joined as a partner. Pfizer will contribute its unique expertise in oncology, immunology, and metabolic disorders as part of the innovative public-private partnership which uses human genetics and genomics data with the aim of improving the success
November 5, 2021 by Chain Drug Review
Pfizer
Pharmacy
NEW YORK — Pfizer’s new experimental antiviral pill to treat COVID-19 cut by 89% the chance of hospitalization or death for adults at risk of severe disease, the company reported on Friday, as its CEO Albert Bourla promised to make it a new weapon in the battle against the pandemic available globally as quickly as
October 7, 2021 by Chain Drug Review
Pfizer
Leading Headlines, Pharmacy
NEW YORK — Pfizer has filed an emergency use authorization application with the Food and Drug Administration for children ages 5 to 11 to receive the COVID-19 vaccine. “With new cases in children in the U.S. continuing to be at a high level, this submission is an important step in our ongoing effort against [COVID-19],”
July 9, 2021 by Chain Drug Review
BioNTech, booster, Covid, Pfizer, vaccine
Leading Headlines
NEW YORK _ Pfizer Inc. and BioNTech will submit data to the Food and Drug Administration in coming weeks supporting a COVID-19 vaccine booster shot. The companies have seen “encouraging data” in the trial of a third dose of their vaccine, they said Thursday. “Initial data from the study demonstrate that a booster dose given
January 22, 2021 by Chain Drug Review
Accumulus Synergy, Amgen, and Takeda, Astellas, Bristol-Myers Squibb, GSK, Lilly, Pfizer, Roche, Sanofi, the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen)
Leading Headlines, Pharmacy
BURLINGAME, Calif. — Ten of the world’s leading biopharmaceutical companies announced the formation of a new non-profit corporation, Accumulus Synergy, which is intended to support interactions between industry and health authorities worldwide to enable real-time collaboration and data exchange, as well as data submission. Accumulus Synergy was formed on July 13, 2020, to develop a
December 14, 2020 by Chain Drug Review
BioNTech SE, COVID-19 vaccine, Pfizer
Leading Headlines, Pharmacy
NEW YORK— Pfizer and BioNTech SE announced additional data on neutralizing antibody and T cell responses from the Phase 1/2 trial with BNT162b2 conducted in Germany. The study results demonstrate that BNT162b2 elicits a combined adaptive humoral and cellular immune response against SARS-CoV-2 and provide insights into the composite nature of BNT162b2-induced T cell immunity.
December 10, 2020 by Chain Drug Review
COVID-19 vaccine, Pfizer
Featured Articles, Leading Headlines, Pharmacy
WASHINGTON— A committee of top U.S. vaccine scientists recommended Thursday that the Food and Drug Administration authorize the first COVID-19 vaccine for Americans. This endorsement paves the way for a final decision by the FDA and mass vaccinations to begin within days in thousands of front-line heath care workers and nursing homes residents. After an
December 10, 2020 by Chain Drug Review
COVID-19 vaccine, Dr. Stephen Hahn, FDA, Pfizer
Leading Headlines, Pharmacy
WASHINGTON — Commissioner Stephen Hahn said ahead of today’s meeting of the Food and Drug Administration’s vaccine advisory panel is “an important day for all of America.” Pfizer’s COVID-19 vaccine faces one last hurdle as it races to become the first shot greenlighted in the U.S. — a panel of experts who will carefully scrutinize
December 2, 2020 by Chain Drug Review
BioNTech SE, COVID-19 vaccine, Pfizer
Leading Headlines, Pharmacy
LONDON — According to various published reports, the U.K. has became the first Western nation to grant emergency-use authorization for a COVID-19 vaccine, clearing a shot developed by Pfizer and BioNTech to be distributed in limited numbers wnext week. The two-shot vaccine is also being reviewed by the Food and Drug Administration in the U.S., where a
November 20, 2020 by Chain Drug Review
BioNTech SE, COVID-19 vaccine, Dr. Albert Bourla, FDA, Pfizer
Leading Headlines, Pharmacy
NEW YORK — Pfizer and BioNTech SE announced they will submit a request Friday to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of their mRNA vaccine candidate, BNT162b2 against SARS-CoV-2, which will potentially enable use of the vaccine in high-risk populations in the U.S. by the middle to end of
November 18, 2020 by Chain Drug Review
COVID-19 vaccine, Pfizer
Leading Headlines, Pharmacy
NEW YORK — Final results from Pfizer Inc’s COVID-19 vaccine trial showed its shot had a 95% success rate and two months of safety data, paving the way for the drugmaker to apply for an emergency U.S. authorization within days, it said on Wednesday. The vaccine’s efficacy rate, the highest of any candidate in late-stage
November 9, 2020 by Chain Drug Review
Albert Bourla, BioNTech, COVID-19, COVID-19 vaccine, Pfizer
Leading Headlines, Pharmacy
NEW YORK — Pfizer announced on Monday that the vaccine the company jointly developed with BioNTech was 90% effective in preventing COVID-19 infections in ongoing Phase 3 trials. Protection in patients was achieved seven days after the second of two doses, and 28 days after the first, according to preliminary findings. “The first set of
October 30, 2020 by Chain Drug Review
mylan, Pfizer, Upjohn
Business, Supplier News
Hertfordshire, England – Mylan and Pfizer announced that the U.S. Federal Trade Commission accepted a proposed consent order, which concludes the FTC’s review of the proposed combination of Mylan and Pfizer’s Upjohn Business. The parties have now obtained all required antitrust clearances for the proposed transaction. The combination will be effected through a Reverse Morris